Signal Breakdown
8 verified publisher articles from recent coverage.
Limited TV coverage this week.
Limited video coverage this week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- Billionaire Ken Griffin is buying AbbVie, signaling high-profile investor interest.
- FDA approved a subcutaneous induction regimen for SKYRIZI in moderate-to-severe Crohn's disease, expanding its gastroenterology opportunity.
- Wall Street still rates AbbVie a buy and the stock is described as an attractive dividend investment.
Risk Factors
- AbbVie reports Q3 earnings on Oct. 30 and options imply an approximately 5% expected move into the print.
- Analysts trimmed guidance last quarter, which limits upside and raises the risk of a negative reaction to disappointing results.
- Shares are up roughly 28.6% year-to-date, which could constrain near-term upside if sentiment cools.
Evidence
- 2026-10-26Source: TIINGO
Summary: Provides the current value of a $100 investment in AbbVie (ABBV) made ten years ago, quantifying the stock's 10-year performance for investors.
Neutral - 2026-10-26Source: TIINGO
Summary: AbbVie reports Q3 before the open on Oct. 30; options imply an approximately 5% expected move while shares are up ~28.6% YTD. After last quarter's guidance trim, limited upside increases the risk of a negative reaction if results disappoint.
Bearish - 2026-10-26Source: TIINGO
Summary: AbbVie set its Q3 earnings conference call for Friday; investors will focus on updates to its immunology franchise and broader healthcare developments.
Neutral - 2026-10-26Source: TIINGO
Summary: Billionaire Ken Griffin is buying AbbVie; despite a high price-to-earnings ratio, Wall Street still rates AbbVie a buy and the stock is described as an attractive dividend investment.
Bullish - 2026-10-25Source: TIINGO
Summary: AbbVie shares at US$285.64 after recent positive immunology and oncology trial results; stock up 197.5% over five years, raising debate whether expected future cash flows justify the current valuation.
Neutral - 2026-10-23Source: GDELT
Summary: FDA approved a subcutaneous induction regimen for AbbVie's SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease, expanding treatment options and likely enhancing SKYRIZI's commercial opportunity in gastroenterology.
Bullish - 2026-10-23Source: GDELT
Summary: FDA approved a subcutaneous induction regimen for AbbVie's SKYRIZI (risankizumab-rzaa) for adults with moderate-to-severe Crohn's disease, expanding SKYRIZI's label and potentially boosting AbbVie's GI franchise revenue.
Bullish - 2026-10-21Source: GDELT
Summary: Insider Monkey published a comparative analysis evaluating AbbVie's earnings-growth story versus AstraZeneca, weighing financial performance, growth drivers, and outlook to determine which company offers stronger earnings momentum.
Neutral
Showing 8 of 8 verified news articles
- No current evidence is available for this source.
No current verified Archive TV segments
- No current evidence is available for this source.
No verified video evidence in the current 7-day window
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.